![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis Gets Nod for Second Kymriah Indication
Novartis Gets Nod for Second Kymriah Indication
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
May 3, 2018
The FDA approved an additional indication for Novartis’ Kymriah (tisagenlecleucel) for relapsed or refractory large B-cell lymphoma.
The indication specifically applies after two or more lines of systemic therapy and includes diffuse large B-cell lymphoma, the most common form of non-Hodgkins lymphoma.
The drug was approved last August for treatment of patients up to 25 years old with B-cell precursor acute lymphoblastic leukemia. The second indication makes Kymriah the only CAR-T cell therapy cleared for two indications.
Upcoming Events
-
21Oct